Alzheimer's disease

News

FDA panel gives unanimous support to Leqembi

The first full regulatory approval for an amyloid-targeting therapy for Alzheimer’s disease could come within a month, after an expert panel voted 6 to 0 in favour of Eisa

News

Eisai files Leqembi in Korea, as US prospects firm up

Eisai has filed for approval of its Alzheimer’s disease therapy Leqembi in South Korea, just ahead of an FDA advisory committee meeting that has raised confidence that the

News

CMS update on Alzheimer's coverage raises questions

The Centres for Medicare and Medicaid Services (CMS) has formally announced its intention to allow coverage of new amyloid-targeting drugs for Alzheimer’s disease if they

R&D

The continued questions over new Alzheimer’s treatments

Hailed as a breakthrough after many years without new treatments for Alzheimer’s disease, a new generation of therapies for the condition have not been welcomed by payers.

News

FDA clears Rexulti as first drug for Alzheimer’s agitation

Lundbeck and Otsuka’s Rexulti has become the first drug to be approved by the FDA to treat agitation associated with Alzheimer’s disease, a common symptom of the neurodege

News

Five takeaways from the new donanemab data

Headlines about the results of TRAILBLAZER-ALZ2 trial of Eli Lilly’s Alzheimer’s drug candidate donanemab are spreading around the world, with some going as far as to sugg

FDA panel gives unanimous support to Leqembi

Eisai files Leqembi in Korea, as US prospects firm up

CMS update on Alzheimer's coverage raises questions

The continued questions over new Alzheimer’s treatments

FDA clears Rexulti as first drug for Alzheimer’s agitation

Five takeaways from the new donanemab data

Novo Nordisk fight with KBP Bio will go to arbitration

Discover a new era of healthcare panel engagement: Grounded ...

Alzheimer's disease

Editor's Picks